Ciclopirox Shortage: What Providers and Prescribers Need to Know in 2026

Ciclopirox is a commonly prescribed broad-spectrum topical antifungal used to treat onychomycosis, tinea infections, cutaneous candidiasis, and seborrheic dermatitis. While ciclopirox is not currently on the FDA's official drug shortage list, prescribers across dermatology, podiatry, and primary care are fielding patient calls about localized stock gaps — particularly for the 8% nail lacquer formulation. This guide provides clinical context for 2026 and practical guidance for managing patients who can't fill their prescription.

Current Availability Status: What the FDA Data Shows

Ciclopirox is not listed on the FDA Drug Shortages Database as of 2026. The medication has been on the U.S. market since 1985 and is produced by multiple generic manufacturers, providing reasonable supply chain redundancy. The active ingredient is manufactured and distributed through standard pharmaceutical supply channels without a documented procurement crisis.

That said, localized availability issues — particularly for the nail lacquer solution and shampoo — are real and patient-reported. These gaps stem from several compounding factors:

Pharmacy inventory prioritization: Smaller and independent pharmacies may not maintain standing stock of specialty formulations, ordering them only upon patient request. This introduces a 1-2 business day delay that patients interpret as unavailability.

Formulation-specific stocking: The five ciclopirox formulations (cream, gel, shampoo, suspension, nail lacquer) each have distinct supply chains. A pharmacy stocked with cream may not have the 8% nail solution on hand.

Seasonal demand patterns: Dermatophytosis and onychomycosis prevalence increases in warmer months, creating demand spikes that pharmacies may not anticipate in their procurement cycle.

Clinical Review: When Is Ciclopirox the Right Choice?

Before discussing alternatives, it's worth considering the evidence base for ciclopirox. For onychomycosis, ciclopirox 8% nail lacquer has complete cure rates of approximately 5-8% — substantially lower than oral terbinafine (70-80%) and newer topical agents like efinaconazole (15-18%). Despite these modest cure rates, ciclopirox remains useful in specific clinical scenarios:

Patients with contraindications to oral antifungals (hepatic impairment, drug interactions)

Mild, limited nail involvement (1-2 nails, <50% nail plate affected)

Post-treatment maintenance after oral antifungal therapy to reduce recurrence

Patients with diabetes where ciclopirox has demonstrated comparable efficacy to the general population with an acceptable safety profile

For tinea pedis, tinea corporis, tinea cruris, and cutaneous candidiasis, ciclopirox cream provides broad-spectrum coverage including dermatophytes, Candida, and Malassezia — making it particularly useful when the organism is unclear. For seborrheic dermatitis, ciclopirox shampoo is supported by Grade A evidence and has demonstrated superior efficacy versus placebo in multiple RCTs.

Evidence-Based Alternatives When Ciclopirox Is Unavailable

The appropriate alternative depends heavily on the indication:

For Onychomycosis

Oral terbinafine 250 mg daily x 12 weeks (toenails) or x 6 weeks (fingernails): First-line oral therapy per AAD and ISHAM guidelines. Requires baseline CBC/CMP; monitor for hepatotoxicity.

Efinaconazole 10% solution (Jublia): Superior topical alternative with higher cure rates. Apply once daily x 48 weeks; no required nail debridement.

Tavaborole 5% solution (Kerydin): Alternative topical boron-based antifungal; FDA-approved for mild to moderate onychomycosis. Daily application x 48 weeks.

Itraconazole pulse therapy: 200 mg BID x 1 week, repeat monthly for 2-3 cycles. Second-line oral option; more drug interactions and cardiac contraindications than terbinafine.

For Tinea Infections (Pedis, Cruris, Corporis)

Terbinafine 1% cream (OTC): Highly effective for dermatophyte infections; 1-2 week courses often sufficient for tinea pedis/cruris.

Clotrimazole or miconazole (OTC): Effective OTC azoles; longer treatment duration (2-4 weeks) than terbinafine cream.

Econazole cream (Rx): Prescription-only alternative with similar spectrum to ciclopirox cream.

For Seborrheic Dermatitis

Ketoconazole 2% shampoo (Rx) or 1% (OTC Nizoral A-D): Direct substitution with comparable evidence base.

Selenium sulfide 2.5% shampoo (Rx) or 1% OTC: Effective maintenance option.

How to Help Your Patients Find Ciclopirox When It Is Available

Patients frequently contact your office frustrated and unsure where to turn. Referring patients to medfinder for providers gives them a practical next step. medfinder contacts pharmacies near the patient to identify which ones can fill the prescription, then texts the patient with results — reducing callbacks to your office and keeping patients on therapy.

See also: How to help your patients find ciclopirox in stock: a provider's guide.